MedTrace Logo

Olmesartan Medoxomil in Hypertension and Renal Impairment

NCT00151827 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 393

Last updated 2010-10-14

No results posted yet for this study

Summary

This is a study in hypertensive patients with mild to moderate renal impairment. The antihypertensive efficacy of olmesartan medoxomil is compared to losartan.

Conditions

  • Essential Hypertension
  • Renal Impairment

Interventions

DRUG

Olmesartan medoxomil

Olmesartan oral tablets 20 or 40 mg + losartan placebo. Medications are taken once daily before breakfast with water.

DRUG

Losartan

Medications are taken once daily before breakfast with water.

DRUG

Furosemide oral tablets

If its use is necessary, the dose of furosemide allowed is 20 to 120 mg per day at the discretion of the investigator

Sponsors & Collaborators

  • Sankyo Pharma Gmbh

    lead INDUSTRY

Principal Investigators

  • P. U. Witte, MD, PhD · IMFORM GmbH, Darmstadt, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-08-31
Primary Completion
2005-07-31
Completion
2005-07-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00151827 on ClinicalTrials.gov